OGT launches new SureSeq Myeloid Fusion Panel to help drive advances in myeloid cancer research 30 Apr 2024 Technology: NGS

Oxford, UK – OGT, a leading global provider of genomic research and diagnostic solutions, announces the launch of the RNA-based SureSeq™ Myeloid Fusion Panel, a new next-generation sequencing (NGS) tool for identifying key fusion genes implicated in acute myeloid leukaemia (AML).

Intelligently designed in collaboration with leading myeloid cancer experts, the SureSeq Myeloid Fusion Panel ensures results meet the latest clinical research recommendations by efficiently identifying over 30 key disease-associated fusions in AML, including KMT2A and MECOM fusions, in a single assay. By utilising a partner-gene agnostic approach, fusions with multiple partners as well as novel and rare fusions can be identified, expanding the ability to classify samples.

This panel is fully compatible with our existing end-to-end Universal NGS Complete Workflow Solution, and complimentary data analysis software, Interpret, to minimise hands-on time and provide easy analysis without the need for additional bioinformatics resource.

“We’re thrilled to be announcing the launch of the SureSeq Myeloid Fusion Panel, the latest addition to OGT’s growing NGS haemato-oncology portfolio” said Adrian Smith, Chief Executive Officer of OGT, “Our substantial experience with genetic technologies, combined with insights from leading myeloid cancer experts, has allowed us to develop a valuable tool for myeloid research, supported by a highly efficient workflow. This will enable users to confidently and rapidly detect the most relevant fusion genes in a single assay.”

The launch of the SureSeq Myeloid Fusion Panel expands OGT’s portfolio to offer more NGS solutions for haematological malignancies and solid tumour cancer research than ever before.

For more information about the SureSeq Myeloid Fusion Panel and OGT’s broad range of genomics solutions, please visit: www.ogt.com/sureseq

About OGT
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists – including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers – not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell®: Some products may not be available in your region.

About Sysmex Corporation
Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of “Together for a better healthcare journey.” Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. The company employs more than 10,000 employees worldwide. Sysmex Corporation is listed in the Prime Market on the Tokyo Stock Exchange.

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.

< | >